| Revenue growth | Revenue +29.2% YoY to Rs 7,910 Cr. |
|---|---|
| Margins | EBITDA margin 24.0% vs 32.9% YoY, 24.1% QoQ. |
| Demand visibility | IPM outperformance; India branded +19%; NA volume expansion; secondary sales +20%. |
Growth
Revenue up 29.2% YoY to Rs 7,910 Cr; NA +21%, India formulations +18%, IM +33%. Reported PAT down 26.6% YoY.
Outlook
No explicit forward guidance; organic capex Rs 466 Cr; net debt Rs 5,200 Cr. Keytruda biosimilar BLA accepted by USFDA.
Risks
EBITDA down 6.0% YoY; margin fell to 24.0% from 32.9%. D&A up 101%, finance cost up 85%.
Last quarter's promises, checked
Delivered
- Strong double-digit FY27 growth → Q2 revenue +29.2% YoY (= BEAT)
- India formulations mid-teens growth → +18% (= BEAT)
- US single-digit growth → NA (US+Canada) +21% (= BEAT)
Partly delivered
- EBITDA margin 24%+ FY27 → 24.0% (= PARTIAL, at floor)
Investor Presentation filed with NSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,199.70
- Market cap
- ₹1,20,718 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 41.3×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Results Update
Zydus Lifesciences reported Q2 FY27 revenue of Rs. 79,096 mn, up 29% y-o-y. H1 net profit was Rs. 18,859 mn, down 31%.
Zydus Lifesciences Other Announcement
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Q2 FY27 Results: Net Profit ₹925.5 Cr, Down 26.6% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹7,910 Cr (+29.2% YoY) and net profit of ₹925.5 Cr (-26.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹925.5 Cr · -26.6% YoY
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.